Current Medical Research and Opinion
February 1, 2024
Dakota Sicignano, Adrían V. Hernández, Benjamin Schiff et al.
19 citations
Critique the available systematic review and de novo assessment of the role of psychedelics in the treatment of alcohol use disorder. A systematic literature search of PubMed was completed from 1960 to 9/9/2023. We pooled randomized controlled trials comparing psychedelics to control therapy for the treatment of alcohol use disorder. At the first recorded follow-up, LSD [n = 3, Odds Ratio (OR)...
BMC Psychiatry
January 26, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
11 citations
A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study is set to evaluate the feasibility and preliminary clinical...
Neuroscience Applied
January 11, 2024
Drummond E-Wen Mcculloch, Matthias E. Liechti, Kim Pc Kuypers et al.
10 citations
Psychedelic drugs including psilocybin and LSD are undergoing clinical trials for a range of psychiatric and neurological conditions, and have particularly shown substantial promise in phase 2 studies of depression. In this article we outline key knowledge gaps that may be imperative for a successful implementation of psychedelic drugs as medicines as identified by members of the European...
Journal of Psychoactive Drugs
2024
Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira et al.
7 citations
Ibogaine is a natural psychoactive drug that has been investigated for its potential role in the treatment of substance use disorders since the mid-1960s. To evaluate the interest in ibogaine's use as a therapeutic agent, we performed a scientometric analysis covering the last three decades (1993-2002, 2003-2012, and 2013-2022). A complementary analysis was performed to select and describe...
Journal of Indira Gandhi Institute Of Medical Sciences
2024
Rakesh Khanna
1 citation
Abstract A review of the literature on posttraumatic stress disorder (PTSD) suggests it to be a complex disorder with many contributing factors. The concept of PTSD has continued to evolve over time. A diagnosis of PTSD may be hard to get right. Studies suggest a wide variation in its presentation and diagnostic stability. It is tempting to explore the possibility of using chemicals that could...
European Journal of Psychotraumatology
2024
Jerome Herpers, Natalie Maximets, Noah N N van Dongen et al.
7 citations
Introduction: The positive results of MDMA from Phase 2 and 3 clinical trials in MDMA-assisted therapy (MDMA-AT) for the treatment of post-traumatic stress disorder (PTSD) call for a critical evaluation of its regulatory status within the European mental healthcare system. This is driven by the recent submission of MDMA-AT for FDA approval in the United States. Unless coordinated efforts in the...
Frontiers in Psychiatry
2024
Chandra Khalifian, K Rashkovsky, E Mitchell et al.
8 citations
Intimate relationship distress is prevalent and is associated with poorer health, mental health, and mortality outcomes. Evidence-based couple therapies target cognitive, behavioral, and emotional processes that underlie relationship dysfunction. Increasing research and clinical evidence supports the efficacy of ketamine-assisted psychotherapy (KAP) for addressing clinical mental health...
PLoS One
2024
Elena Argento, Tashia Petker, Jayesh Vig et al.
3 citations
This study explores therapists' perspectives on experiential learning, competencies, and training in ketamine-assisted therapy (KAT), a form of psychedelic-assisted therapy (PAT). We aim to understand how therapists' personal psychedelic experiences influence their self-perceived competency and therapeutic relationships regarding KAT. Licensed therapists from Numinus Wellness clinics in Canada...
Frontiers in Psychology
2024
Kelley C O'Donnell, Lauren Okano, Michael Alpert et al.
Results from multiple recent studies support further evaluation of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e., MDMA-Assisted Therapy) in the treatment of post-traumatic stress disorder (PTSD). In two Phase 3 trials, MDMA-Assisted Therapy comprised a short-term, intensive psychotherapy that included three sessions directly facilitated by MDMA (referred to as...
Journal of Addictive Diseases
2024
Alexandra Arenson, Cynthia I Campbell, Ilan Remler
8 citations
The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternative treatments. This narrative review aims to educate clinicians on the mechanisms of action, toxicity, and applications of psychoactive plant-based substances patients may be using to self-treat OUD and OW. We specifically discuss ayahuasca, ibogaine,...